Diastereoselective synthesis of γ-amino-δ-hydroxy-α, α-difluorophosphonates: A vehicle for structureactivity relationship studies on SMA-7, a potent sphingomyelinase inhibitor

Journal of Organic Chemistry

Volumn 74, Issue 16, 2009, Pages 6350-6353

  Yamagishi, Takehiro ^a   Muronoi, Shin ^a   Hikishima, Sadao ^a   Shimeno, Hiroshi ^b   Soeda, Shinji ^b   Yokomatsu, Tsutomu ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ALCOHOLS; CHEMICAL EQUATIONS; DIASTEREOSELECTIVE SYNTHESIS; PHOSPHONATES; POTENT INHIBITOR; SPHINGOMYELINASE; STRUCTURE ACTIVITY RELATIONSHIPS;

ALCOHOLS; AMINATION; KETONES; STEREOSELECTIVITY;

AMINES;

GAMMA AMINO DELTA HYDROXY ALPHA,ALPHA DIFLUOROPHOSPHONATE; PHOSPHONIC ACID DERIVATIVE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; ALKANE; ENZYME INHIBITOR; ORGANOPHOSPHORUS COMPOUND; SMA-7 COMPOUND; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE;

ARTICLE; CHEMICAL STRUCTURE; STEREOCHEMISTRY; SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYME SPECIFICITY; PC12 CELL LINE; RAT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ALKANES; ANIMALS; ENZYME INHIBITORS; ORGANOPHOSPHORUS COMPOUNDS; PC12 CELLS; PHOSPHONIC ACIDS; RATS; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; ORGANOPHOSPHONATES;

EID: 70349125444     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo9008782     Document Type: Article

References (33)

1. For reviews, see: (a) Wymann, M. P.; Schneiter, R. Nat. Rev. Mol. Cell Biol. 2008, 9, 162.
2. (b) Ledeen, R. W.; Wu, G. J. Lipid Res. 2008, 49, 1176.
3. (c) Hannun, Y. A.; Luberto, C.; Argraves, K. M. Biochemistry 2001, 40, 4893.
4. (d) Kolter, T.; Sandhoff, K. Angew. Chem., Int. Ed. 1999, 38, 1532.
5. For a review of SMase, see: Montes, L. R.; Goni, F. M.; Alonso, A. Sphingolipids Cell Funct. 2006, 53.
6. For select examples on the preparation of SMase inhibitors, see: (a) Kornhuber, J.; Tripal, P.; Reichel, M.; Terfloth, L.; Bleich, S.; Wiltfanf, J.; Gulbins, E. J. Med. Chem. 2008, 51, 219.
7. (b) Inoue, M.; Yokota, W.; Katoh, T. Synthesis 2007, 622.
8. (c) Wascholowski, V.; Giannis, A. Angew. Chem., Int. Ed. 2006, 45, 827 and references cited therein.
9. Amtmann, E.; Zoeller, M. Biochem. Pharmacol. 2005, 69, 1141.
10. Chatterjee, S. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1523.
11. (a) Yokomatsu, T.; Takechi, H.; Akiyama, T.; Shibuya, S.; Kominato, T.; Soeda, S.; Shimeno, H. Bioorg. Med. Chem. Lett. 2001, 11, 1227.
12. (b) Yokomatsu, T.; Murano, T.; Akiyama, T.; Koizumi, J.; Shibuya, S.; Tsuji, Y.; Soeda, S.; Shimeno, H. Bioorg. Med. Chem. Lett. 2003, 13, 229.
13. Katsumura and co-workers independently reported that the DFMP analogue of sphingomyelin inhibits SMase competitively, see: Hakogi, T.; Yamamoto, T.; Fujii, S.; Ikeda, K.; Katsumura, S. Tetrahedron Lett. 2006, 47, 2627.
14. (a) Soeda, S.; Sakata, A.; Ochiai, T.; Yasuda, K.; Shimeno, H.; Toda, A.; Eyanagi, R.; Hikishima, S.; Yokomatsu, T.; Shibuya, S. Curr. Drug Therapy 2008, 3, 218.
15. (b) Soeda, S.; Tsuji, Y.; Ochiai, T.; Mishima, K.; Iwasaki, K.; Fujiwara, M.; Yokomatsu, T.; Murano, T.; Shibuya, S.; Shimeno, H. Neurochem. Int. 2004, 45, 619.
16. (c) Sakata, A.; Ochiai, T.; Shimeno, H.; Hikishima, S.; Yokomatsu, T.; Shibuya, S.; Toda, A.; Eyanagi, R.; Soeda, S. Immunology 2007, 122, 54.
17. (d) Sakata, A.; Yasuda, K.; Ochiai, T.; Shimeno, H.; Hikishima, S.; Yokomatsu, T.; Shibuya, S.; Soeda, S. Cellular Immunol. 2007, 245, 24.
18. (a) Otaka, A.; Miyoshi, K.; Burke, T. R., Jr.; Roller, P. P.; Kurobe, H.; Tamamura, H.; Fujii, N. Tetrahedron Lett. 1995, 36, 927.
19. (b) Berkowitz, D. B.; Eggen, M.; Shen, Q.; Shoemarker, R. K. J. Org. Chem. 1996, 61, 4666.
20. Martin, S.M.; Dean, D.W.; Wagman, A.S. Tetrahedron Lett. 1992, 33, 1839.
21. (a) Ozturk, T.; Ertas, E.; Mert, O. Chem. Rev. 2007, 107, 5210.
22. (b) Jesberger, M.; Davis, T. P.; Barner, L. Synthesis 2003, 1929.
23. (c) Cava, M. P.; Levinson, M. I. Tetrahedron 1985, 41, 5061.
24. Yokomatsu, T.; Sato, M.; Shibuya, S. Tetrahedron: Asymmetry 1996, 7, 2743.
25. Murano, T.; Yuasa, Y.; Kobayakawa, H.; Yokomatsu, T.; Shibuya, S. Tetrahedron 2003, 59, 10223.
26. Yields refers to those from crude aldehyde 2 and not optimized.
27. An accurate yield was not caluculated because of some inseparable impurities included.
28. For the preparation of amino ketones 5, we have synthesized the Weinreb amide derived from alcohol 11 and examined the reaction with a large excess of vinyl magnesium bromide (THF/0 °C to rt). However, the Weinreb amide was found to be inert to the Grignad reagent under our experimental conditions. In a series of the phosphonothiate analogues, we failed to prepare the correponding carboxylate due to significant decomposition of 12 during oxidation. Therefore, we could not examine the reactivity of the Weinreb amide, derived from alcohol 12, to the Grignard reagent.
29. To obtain the required amino alcohol derivertives in a stereoselective manner, an alternative method may be available on the basis of sequential DIBAL-mediated reduction and alkylation with a Grignard reaction toward amino esters in one pot. (a) Polt, R.; Peterson, M. A.; DeYong, L. J. Org. Chem. 1992, 57, 5469.
30. (b) Polt, R.; Peterson, M. A. Tetraherdon Lett. 1990, 31, 4985. However, in the present studies, we focused on the alkylation-oxidationreduction sequence starting from aldehydes 1 and 2.
31. (a) Hoffman, R. V.; Maslouh, N.; Cervantes-Lee, F. J. Org. Chem. 2002, 67, 1045.
32. (b) Davis, F. A.; Gaspari, P. M.; Nolt, B. M.; Xu, P. J. Org. Chem. 2008, 73, 9619.
33. Lopin, C.; Gautier, A.; Gouhier, G.; Piettre, S. R. J. Am. Chem. Soc. 2002, 124, 14668.